~~<i id='7CEA9F116A'><strike id='7CEA9F116A'><tt id='7CEA9F116A'><pre id='7CEA9F116A'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

fashion

author：focus 2025-10-01 22:49:32 - browse：4

Aduhelm, a pioneering treatment for Alzheimer’s disease that collapsed under corporate mistakes and regulatory controversy, is now a cautionary tale in pharmaceutical history.

This week Biogen said it would no longer sell or study the medicine, which first won approval in 2021, ending an era for one of biotech’s storied companies and leaving the rest of the industry to piece together the lessons of a would-be blockbuster that never took off.

STAT reporters took a stab at the Aduhelm legacy — for biotech, Biogen, and Alzheimer’s research — on a recent episode of the Readout LOUD. Here’s an edited transcript of that conversation.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： What nurses really want: sufficient staffing for patient care

Wikipedia

hotspot

focus

explore

Wikipedia

NorthCountryHealthCareInKingman,Ariz.,awindsweptcityof35,000attheeasternedgeoftheMojavedesert,datasc

WSS

Study: Adult vaccinations pay for themselves in societal benefits

The lessons of Aduhelm, an Alzheimer's drug that was not to be

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

Telehealth startups turn to complex chronic diseases

Readout LOUD podcast: What to know about H5N1 bird flu

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

knowledge

fashion

Wikipedia

The high cost of giving birth even with insurance

Some dementia cases could be undiagnosed liver disease

Drug repurposing or repositioning? The language matters

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

Novavax promises a turnaround & Lilly roils the obesity market

Quicker fix for pulse oximeters urged during FDA public meeting

23andMe had bad news about my health. I wish a person had delivered it

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

Activists slam private health insurers over coverage restrictions

Study: AI not yet building 'n

hotspot

Juul spent big to court Black leaders to promote its e

Shionogi licenses Pompe disease therapy from Maze Therapeutics

Quicker fix for pulse oximeters urged during FDA public meeting

Researchers on aging grapple with how to calculate biological age

General Catalyst, Summa Health deal will turn on physician buy

The lessons of Aduhelm, an Alzheimer's drug that was not to be

focus

focus

explore

Wikipedia